24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring
- 1 December 1997
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 15 (12) , 1511-1518
- https://doi.org/10.1097/00004872-199715120-00020
Abstract
To compare 24 h ambulatory blood pressure and trough office blood pressure lowerings after 8 weeks of therapy with 75 mg irbesartan once a day, 150 mg irbesartan once a day, and 75 mg irbesartan twice a day versus placebo; and to assess safety and tolerability of irbesartan therapy. Multicenter, double-blind, randomized, placebo-controlled trial. Sixteen centers in Italy. Caucasian patients (n = 215) aged ≥ 18 years with seated diastolic blood pressure 95–110 mmHg and ambulatory diastolic blood pressure (ADBP) ≥ 85 mmHg. Mean 24 h ADBP after 8 weeks of irbesartan therapy. Mean changes (value before treatment minus value after treatment) in ADBP for placebo, 75 mg irbesartan once a day, 150 mg irbesartan once a day, and 75 mg irbesartan twice a day were −0.2, −5.4, −7.2, and −7.2 mmHg, respectively; respective changes in ambulatory systolic blood pressure were +1.6, −8.3, −10.5, and −9.7 mmHg. All irbesartan regimens reduced trough office seated diastolic blood pressure and seated systolic blood pressure after 2 and 8 weeks of treatment (all P < 0.01, versus placebo except for seated systolic blood pressure in patients in the 75 mg irbesartan once a day group). Trough: peak ratios were ≥ 55% with 150 mg irbesartan once a day. Percentages of patients whose blood pressures were normalized with 150 mg irbesartan once a day (45%) and 75 mg irbesartan twice a day (47%) were greater than those with placebo (14%, P < 0.01) and with 75 mg irbesartan once a day (19%, NS, versus placebo). Adverse events with irbesartan were similar to those with placebo. All irbesartan regimens significantly reduced mean 24 h ADBP and ambulatory systolic blood pressure, and were well tolerated. Administration of 150 mg irbesartan once a day provided significant reduction of blood pressure for 24 h, equivalent to that obtained with the same daily dose divided into two separate administrations.Keywords
This publication has 16 references indexed in Scilit:
- Dose-Ranging Study of the Angiotensin II Receptor Antagonist Irbesartan (SR 47436/BMS-186295) on Blood Pressure and Neurohormonal Effects in Salt-Deplete MenJournal of Cardiovascular Pharmacology, 1996
- The antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.American Journal of Hypertension, 1996
- Ambulatory blood pressure normalityJournal Of Hypertension, 1995
- Calculation of trough: peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspectsJournal Of Hypertension, 1995
- Lack of placebo effect on ambulatory blood pressureAmerican Journal of Hypertension, 1995
- Hemodynamic and Biochemical Effects of the AT 1 Receptor Antagonist Irbesartan in HypertensionHypertension, 1995
- Ethnicity and the relationship of sodium intake to blood pressureJournal Of Hypertension, 1994
- TroughJournal Of Hypertension, 1994
- Limited reproducibility of hourly blood pressure values obtained by ambulatory blood pressure monitoringJournal Of Hypertension, 1992
- How important is heart rate?Journal Of Hypertension, 1991